论文部分内容阅读
随着对原发性青光眼发病机制认识的不断深入 ,以降眼压为主的治疗模式正在发生变化。其中钙通道阻滞剂作为治疗原发性青光眼的一类新型药物 ,已得到普遍关注 ,尤其在正常眼压性青光眼的治疗方面具有不可替代的作用。钙通道阻滞剂通过与细胞膜上钙通道结合 ,减少钙离子内流 ,从而扩张血管 ,缓解痉挛 ,改善视神经乳头的血供。另外 ,钙通道阻滞剂还具有功能性拮抗血管内皮素及降低眼压、保护视神经、抑制成纤维细胞粘附和增生等作用。
With the deepening understanding of the pathogenesis of primary glaucoma, the treatment mode of lowering intraocular pressure is changing. Among them, calcium channel blockers, as a new class of drugs for the treatment of primary glaucoma, have received widespread attention and have an irreplaceable role in the treatment of normal-tension glaucoma. Calcium channel blockers through the cell membrane with calcium channels to reduce the influx of calcium, which dilates blood vessels, relieve spasms, improve blood supply to the optic nerve head. In addition, calcium channel blockers also have a functional antagonism of endothelin and reduce intraocular pressure, protect the optic nerve, inhibit fibroblast adhesion and proliferation and so on.